title: [Frontal brain volume reduction due to antipsychotic drugs?].
abstract: This article reviews the results of longitudinal studies on frontal brain volume reduction in patients with schizophrenia spectrum disorders and focuses on the relationship with antipsychotic treatment. Based on a systematic literature search all studies were included in which results on changes of brain volumes over a longer period of time were correlated with antipsychotic treatment dose and disease severity. The findings indicate that there is evidence for grey and white matter volume changes of the frontal brain, which cannot be explained by the severity of the disease alone but are also very likely a manifestation of long-term effects of antipsychotics. Whether second generation antipsychotics have an advantage compared to first generation antipsychotics is currently unclear. Considering the contribution of antipsychotics to the changes in brain structure, which seem to depend on cumulative dosage and can exert adverse effects on neurocognition, negative and positive symptoms and psychosocial functioning, the guidelines for antipsychotic long-term drug treatment should be reconsidered. This is the reason why we and others recommend prescribing the lowest dose necessary to control symptoms. In non-schizophrenic psychiatric disorders, antipsychotics should be used only with great caution after a careful risk-benefit assessment. Moreover, treatment approaches which can help to minimize antipsychotic medication or even administer them only selectively are of increasing importance.
authors.affiliation: Institut für Sozialpsychiatrie, Ernst-Moritz-Arndt-Universität Greifswald, Ellernholzstr. 1-2, 17487, Greifswald, Deutschland, volkmar.aderhold@uni-greifswald.de.
authors.forename: V
authors.initials: V
authors.lastname: Aderhold
authors.forename: S
authors.initials: S
authors.lastname: Weinmann
authors.forename: C
authors.initials: C
authors.lastname: Hägele
authors.forename: A
authors.initials: A
authors.lastname: Heinz
mesh_terms: D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D001284:Atrophy / Q000139:chemically induced / Q000473:pathology; D001921:Brain / Q000187:drug effects / Q000473:pathology*; D019317:Evidence-Based Medicine; D006801:Humans; D009929:Organ Size / Q000187:drug effects; D012559:Schizophrenia / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology*; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents